Crucell, DSM Biologics N.V., Synco Bio Partners Investments, Synergenics LLC deal

Synco and Synergenics licensed rights to use CRXL's PER.C6 technology to develop monoclonal antibodies for infectious diseases. CRXL and its contract manufacturing partner, DSM, will receive an upfron...